References
- Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8.
- Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020 Sep 8;324(10):951–60. doi:10.1001/jama.2020.15543.
- Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. doi:10.1016/S1473-3099(20)30843-4.
- Palacios R, Batista AP, Albuquerque CSN, Patiñoet EG, Santos JP, Conde MTRP, Piorelli RO, Júnior LCP, Raboni SM, Ramos F, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study (Pre-print, April 14, 2021). https://ssrn.com/abstract=3822780 . Accessed May 29, 2021
- Bueno SM, Abarca K, Gonzalez PA, Galvez NMS, Soto JA, Duarte LF, Schultz BM, Pacheco GA, Gonzalez LA, Vazquez Y, et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. (Preprint, April 01, 2021). https://www.medrxiv.org/content/10.1101/2021.03.31.21254494v1 . Accessed May 29, 2021
- Ranzani OT, Hitchings M, Nieto MD, D’Agostini TL, Paula RC, Paula OFP, Villela EFM, Torres MSS, Oliveira SB, Almiron M, et al. Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: a test-negative case-control study. (Preprint, May 21, 2021). https://europepmc.org/article/PPR/PPR344222 . Accessed May 29, 2021
- Pan H, Liu J, Huang B, Li G, Chang X, Liu Y, Wang W, Chu K, Hu J, Li J, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (KCONVAC) in healthy adults: two randomized, double-blind, and placebo-controlled phase 1/2 clinical trials. (Preprint, April 08, 2021). https://www.medrxiv.org/content/10.1101/2021.04.07.21253850v1 . Accessed May 29, 2021
- Yang L, Li L, Lu Q, Shi N. A comparative study of vaccination program of two doses varicella vaccine (live) freeze dried with different intervals (in Chinese). Prog Microbiol Immunol. 2015;43(6):10–13. doi:10.13309/j.cnki.pmi.2015.06.003.
- Yin G, Mao Y, Wang B, Yan J, Liu Y. Observation on immune effect of yeast-derived recombinant Hepatitis B vaccine (in Chinese). Mod. 2002(3):319–20. doi:10.3969/j.issn.1006-916X.2001.02.014.
- [accessed 2021 May 29]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_2275/202012/t20201228_223494.html.